Remed
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Remed makes medical devices that use powerful magnetic fields and other energy-based technologies to treat neurological and psychiatric conditions, such as depression, ADHD, and stroke, as well as to manage pain and support physical rehabilitation, all without surgery.
Its products are used in clinical and hospital settings by medical professionals. The company's portfolio spans brain-stimulation devices, pain-management systems, and energy-based aesthetic and dermatology equipment, giving it a broad range across both therapeutic and cosmetic medical applications. Remed is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Remed in five facts
What does Remed do?
Remed makes medical devices that use powerful magnetic fields and other energy-based technologies to treat neurological and psychiatric conditions, such as depression, ADHD, and stroke, as well as to manage pain and support physical rehabilitation, all without surgery.
Where is Remed listed and in which sector?
Remed (Korean name: 리메드) trades under KRX code 302550 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Remed?
Its market capitalisation was US$54.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Remed's latest annual revenue and operating profit?
For fiscal year 2025, Remed reported revenue of US$18.5M, operating profit of US$547.8K and a net loss of US$26.8K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 4.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 20
- Share cancellation decisionOct 19
- [Amended] Material event report (convertible bonds)
Remed updated the terms of convertible bonds to raise US$7.53M, about 14.0% of its market value.
Capital raise · Oct 19 · 2 versions - Executives/major shareholders' securities trading planOct 14
- [Amended] Supply contract signed
Remed updated a previously disclosed supply contract with Zimmer MedizinSysteme GmbH, now worth US$17.4M, about 140.9% of its recent annual revenue, running through Oct 2031.
Supply contract · Sep 29 - Report on large shareholdings (5% rule) (standard)Sep 23
- Report on large shareholdings (5% rule) (standard)Sep 18
- Report on large shareholdings (5% rule) (standard)Sep 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Remed reported consolidated results for FY2025: revenue of US$17M (−4.1% year on year), operating profit of US$504K (−35.3% year on year) and a net loss of US$122K (from a profit a year earlier).
Earnings · Feb 25